Read + Share
Bagley SJ. Phase 2 trials in the era of glioblastoma immunotherapy: New mechanisms of
action, familiar challenges in trial design and tumor response assessment. Neuro Oncol 2023 Feb 15:noad043. doi: 10.1093.
PMID: 36789741
|
 |
|
Bagley SJ. Phase 2 trials in the era of glioblastoma immunotherapy: New mechanisms of
action, familiar challenges in trial design and tumor response assessment. Neuro Oncol 2023 Feb 15:noad043. doi: 10.1093.
PMID: 36789741
|
|
|
|